Table 1 Baseline demographic and clinical data concerning the study cohort
Total number of patients | 20 |
|---|---|
Age (years)a | 61 (36–85) |
Sex | |
Female | 11 (55) |
Male | 9 (45) |
Relationship status | |
Married | 9 (45) |
Cohabiting | 3 (15) |
Single | 8 (40) |
Children | |
Yes | 16 (80) |
No | 4 (20) |
Time since primary diagnosis (years)a | 8 (2–22) |
Time receiving systemic treatment (years)a | 6 (2–15) |
Primary tumour localisation | |
Stomach | 12 (60) |
Small bowel | 7 (35) |
Rectum | 1 (5) |
KIT/PDGFRA mutations | |
KIT exon 11 | 11 (55) |
KIT exon 9 | 3 (15) |
KIT exon 13 | 1 (5) |
PDGFRA exon 18 | 1 (5) |
PDGFRA exon 12 | 1 (5) |
Not detected | 3 (15) |
Metastatic site | |
Liver | 10 (50) |
Peritoneal | 8 (40) |
Liver and peritoneal | 2 (10) |
Metastasis at diagnosis | |
Yes | 10 (50) |
No | 10 (50) |
Previous adjuvant imatinib treatment (12–36 months) | |
Yes | 5 (25) |
No | 15 (75) |
Systemic treatment in a metastatic setting | |
Imatinib | 18 (90) |
Sunitinib | 2 (10) |
Number of surgeries (including surgery to the primary tumour) | |
No surgery | 1 (5) |
1 | 10 (50) |
2 | 8 (40) |
5 | 1 (5) |
Radiotherapy | |
Yes | 2 (10) |
No | 18 (90) |